A Study of LY4257496 in Participants With Cancer (OMNIRAY)
Phase 1
421
about 9.7 years
18+
15 sites in CA, FL, GA +5
What this study is about
Researchers are testing a treatment called LY4257496 alone and with standard cancer treatments in people with certain types of advanced cancers. The trial will last up to 36 weeks or until the cancer progresses.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take LY4257496
- 2.Take Standard of Care Anticancer Therapies
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Primary: Phase 1a Dose Escalation: Maximum Tolerated Dose of LY4257496, Phase 1b Dose Expansion and Optimization: Objective Response Rate (ORR): Percentage of Participants with Best Response of Complete Response (CR) or Partial Response (PR)
Secondary: Phase 1a Dose Escalation PK: Area Under the Curve (AUC) of LY4257496, Phase 1a Dose Escalation Pharmacokinetics (PK): Maximum Drug Concentration (Cmax) of LY4257496, Phase 1a Dose Escalation and Optimization PK: AUC of LY4257529, Phase 1a Dose Escalation and Optimization PK: Cmax of LY4257529, Phase 1a Dose Escalation and Optimization: ORR: Percentage of Participants with Best Response of CR or PR
Oncology